Physicians Face License Risk Over Unapproved CMS Hemp Products

CMS Coverage Expands Faster Than FDA Review Process

At least 14 state Medicaid programs now cover hemp-derived CBD and minor cannabinoid products that haven't received FDA approval as drugs or dietary supplements. The Centers for Medicare & Medicaid Services hasn't issued formal guidance on whether coverage decisions require prior FDA clearance, leaving individual state programs to interpret federal law independently.

The cleanest read on the disconnect? Administrative expedience. State Medicaid directors facing constituent pressure to cover cannabinoid therapies are moving forward with coverage determinations based on clinical evidence submissions from manufacturers, bypassing the FDA's New Drug Application process entirely. CMS hasn't blocked these coverage decisions, but it hasn't endorsed them either.

The FDA maintains that any hemp product marketed with disease claims must go through drug approval channels. No hemp-derived product except Epidiolex has cleared that bar. Yet state formularies now list hemp extracts for conditions ranging from chronic pain to PTSD, creating a prescribing environment where doctors must choose between patient access and regulatory compliance.

State Medical Boards Flag Prescribing Risk

At least six state medical boards have issued advisories warning physicians that prescribing unapproved substances may constitute unprofessional conduct under state practice acts. The advisories stop short of blanket prohibitions. They emphasize that doctors bear liability for prescribing products without established safety profiles.

California's Medical Board issued a March 2026 bulletin noting that physicians who prescribe hemp products not approved by the FDA "assume full responsibility for patient outcomes and may face disciplinary action if harm results." Ohio's State Medical Board issued similar language in April, adding that malpractice insurers may decline coverage for claims arising from unapproved hemp prescriptions.

The risk calculus is stark. A physician who writes a prescription for a CMS-covered hemp product that later causes an adverse event could face both a malpractice suit and a medical board complaint, with no FDA-approved labeling or clinical trial data to support the prescribing decision. CMS coverage doesn't shield the physician from state-level professional discipline.

Manufacturers Exploit the Coverage-Approval Gap

Hemp manufacturers are marketing directly to physicians with claims that CMS coverage constitutes de facto federal endorsement, a framing that regulators call misleading. At least three companies have sent mailers to primary care practices highlighting Medicaid reimbursement codes for their products while omitting any mention of FDA approval status.

The FDA sent warning letters to two hemp manufacturers in April 2026 for making therapeutic claims without drug approval. One company had marketed a hemp extract as "CMS-approved for neuropathic pain," a claim the FDA called false and misleading because CMS coverage decisions don't confer drug approval. The company removed the language from its website but continues to list Medicaid billing codes in physician-facing materials.

Doctors who rely on CMS formulary listings as a proxy for safety and efficacy may not realize they're prescribing substances that have never undergone Phase III trials or FDA toxicology review, creating an information asymmetry that favors manufacturers. The result is a prescribing environment where regulatory signals point in opposite directions.

What Physicians Should Watch

The FDA is expected to issue a final rule on hemp-derived cannabinoid products by the end of 2026, which may clarify whether CMS coverage can proceed without drug approval. Until then, physicians face a binary choice: prescribe the products and accept professional liability risk, or decline to prescribe and risk losing patients to providers willing to take that risk.

The next signal to watch is whether any state medical board brings a disciplinary case against a physician for prescribing a CMS-covered hemp product. No such case has been filed yet. But the advisories suggest boards are preparing the legal groundwork. For full background on this regulatory conflict, see the CannIntel topic hub on FDA hemp regulation.

Physicians in states with active Medicaid hemp coverage should document informed consent conversations with patients, noting that the products lack FDA approval and that long-term safety data don't exist. That documentation may not prevent a board complaint, but it establishes that the physician disclosed the regulatory uncertainty. The safest legal position remains not prescribing at all.